Utilization of patient-reported outcomes to assess adherence to relugolix when combined with stereotactic body radiation therapy for intermediate to high-risk prostate cancer. - Gaudian K; Koh MJ; Collins RR; Eden S; Zwart Z; Danner M; Zwart A; Fallick M; Kumar D; Leger P; Dawson NA; Suy S; et al. (Frontiers in oncology, 2025)